Cardiotoxicity in BRAF/MEK-Treated Melanoma: A Manageable but Underrecognized Risk
BRAF/MEK inhibitors improve survival in metastatic melanoma but carry a significant risk of cardiotoxicity. Our real-world study found a 21% incidence of LVEF-reduction in a Danish patient cohort, primarily within the first year. Most cases were reversible, underscoring the need for monitoring and individualized management.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
